S. Seeber

584 total citations
55 papers, 445 citations indexed

About

S. Seeber is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, S. Seeber has authored 55 papers receiving a total of 445 indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Oncology, 25 papers in Pulmonary and Respiratory Medicine and 9 papers in Molecular Biology. Recurrent topics in S. Seeber's work include Colorectal Cancer Treatments and Studies (19 papers), Cancer Treatment and Pharmacology (17 papers) and Lung Cancer Treatments and Mutations (10 papers). S. Seeber is often cited by papers focused on Colorectal Cancer Treatments and Studies (19 papers), Cancer Treatment and Pharmacology (17 papers) and Lung Cancer Treatments and Mutations (10 papers). S. Seeber collaborates with scholars based in Germany, United States and United Kingdom. S. Seeber's co-authors include U. Vanhoefer, U. Klaassen, N. Schleucher, A. Harstrick, Tanja Trarbach, Dirk Strumberg, H. Wilke, Eric Masson, U. Junker and M. E. Scheulen and has published in prestigious journals such as Journal of Clinical Oncology, International Journal of Radiation Oncology*Biology*Physics and Annals of Oncology.

In The Last Decade

S. Seeber

51 papers receiving 428 citations

Peers

Countries citing papers authored by S. Seeber

Since Specialization

Citations

This map shows the geographic impact of S. Seeber's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S. Seeber with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S. Seeber more than expected).

Fields of papers citing papers by S. Seeber

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by S. Seeber. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S. Seeber. The network helps show where S. Seeber may publish in the future.

Co-authorship network of co-authors of S. Seeber

This figure shows the co-authorship network connecting the top 25 collaborators of S. Seeber. A scholar is included among the top collaborators of S. Seeber based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with S. Seeber. S. Seeber is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A dynamic anthropomorphic phantom for end‐to‐end testing in image‐ and surface‐guided adaptive radiotherapy 2025 ·Medical Physics ·(unknown), A. Runz, Ricardo Augusto, Gernot Echner, (unknown), Gabriel Rinaldi, P. Haering, (unknown), S. Seeber, (unknown), Benjamin Ackermann, Reynam C. Pestana, (unknown), Fabian Weykamp, (unknown), (unknown), Vania Batista, Oliver Jäkel, Christian P. Karger	0
2	An abdominal phantom with anthropomorphic organ motion and multimodal imaging contrast for MR-guided radiotherapy 2022 ·Physics in Medicine and Biology ·(unknown), (unknown), (unknown), (unknown), (unknown), S. Seeber, Regula Gnirs, A. Runz, Gernot Echner, Christian P. Karger, Oliver Jäkel	12
3	Randomized phase III trial in locally advanced squamous cell carcinoma of the esophagus: Neoadjuvant radiochemotherapy followed by surgery vs. definitive radiochemotherapy 2004 ·International Journal of Radiation OncologyBiologyPhysics ·Martin Stuschke, M. Stahl, H. Wilke, Martin K. Walz, S. Seeber, Bodo Klump, Wilfried Budach, H. D. Becker, D. Haeussinger, G Schmitt, (unknown)	1
4	Ernährung, Lifestyle und Krebs: Wege zur Primärprävention 2004 ·DMW - Deutsche Medizinische Wochenschrift ·Dirk Strumberg, Heiner Boeing, M. E. Scheulen, H Förster, S. Seeber	1
5	Pharmacokinetics of treosulfan in a myeloablative combination with cyclophosphamide prior to allogeneic hematopoietic stem cell transplantation 2004 ·International Journal of Clinical Pharmacology and Therapeutics ·Ralf A. Hilger, Joachim Baumgart, M. E. Scheulen, Rudolf Trenschel, Dirk Strumberg, S. Seeber, Dietrich W. Beelen	5
6	Results of a phase I trial of BAY 43–9006 in combination with doxorubicin in patients with refractory solid tumors 2004 ·Journal of Clinical Oncology ·Heike Richly, P. Kupsch, (unknown), (unknown), Ralf A. Hilger, Catherine G. Haase, Brian Schwartz, M. E. Scheulen, S. Seeber, Dirk Strumberg	17
7	A randomized phase I study of the humanized anti-epidermal growth factor receptor (EGFR) monoclonal antibody EMD 72000 in subjects with advanced gastrointestinal cancers 2004 ·Journal of Clinical Oncology ·Tanja Trarbach, Thomas Beyer, N. Schleucher, J. Stattaus, Stefan Müeller, (unknown), J. Tillner, K. W. Schmid, S. Seeber, U. Vanhoefer	11
8	A randomized phase I study of the humanized anti-epidermal growth factor receptor (EGFR) monoclonal antibody EMD 72000 in subjects with advanced gastrointestinal cancers 2004 ·Journal of Clinical Oncology ·Tanja Trarbach, Thomas Beyer, N. Schleucher, J. Stattaus, Stefan Müeller, (unknown), J. Tillner, K. W. Schmid, S. Seeber, U. Vanhoefer	4
9	A phase I clinical and pharmacokinetic study of the Raf kinase inhibitor (RKI) BAY 43-9006 administered in combination with doxorubicin in patients with solid tumors 2003 ·International Journal of Clinical Pharmacology and Therapeutics ·Heike Richly, P. Kupsch, (unknown), M. Grubert, (unknown), (unknown), D. Voliotis, M. E. Scheulen, S. Seeber, Dirk Strumberg	21
10	A summary of two clinical studies on tumor cell dissemination in primary and metastatic breast cancer: Methods, prognostic significance and implication for alternative treatment protocols (Review) 2002 ·International Journal of Oncology ·Sabine Kasimir‐Bauer, C. Oberhoff, A. E. Schindler, S. Seeber	11
11	Maintenance treatment with medroxyprogesterone acetate in patients with advanced breast cancer responding to chemotherapy: results of a randomized trial 1999 ·Breast Cancer Research and Treatment ·O. Kloke, U. Klaassen, C. Oberhoff, (unknown), J. Szántó, (unknown), Markus Heckmann, (unknown), (unknown), (unknown), (unknown), (unknown), R. Rudolph, Andrew E. Berke, (unknown), (unknown), H. Hirche, A. E. Schindler, S. Seeber, R. Becher	31
12	Paclitaxel plus ifosfamide in advanced ovarian cancer 1998 ·Anti-Cancer Drugs ·U. Klaassen, A. Harstrick, Dirk Strumberg, Hans‐Joachim Wilke, S. Seeber	5
13	Drug interactions of 5-fluorouracil with either cisplatin or lobaplatin???a new, clinically active platinum analog in established human cancer cell lines 1997 ·Anti-Cancer Drugs ·A. Harstrick, U. Vanhoefer, (unknown), (unknown), Hans‐Joachim Wilke, S. Seeber	5
14	Simulation of 3D-treatment plans in head and neck tumors aided by matching of digitally reconstructed radiographs (DRR) and on-line distortion corrected simulator images 1997 ·Radiotherapy and Oncology ·Frank Lohr, Oliver Schramm, P. Schraube, G. Sroka-Pérez, S. Seeber, (unknown), (unknown), M. Wannenmacher	12
15	Infusional 5-FU, folinic acid, paclitaxel, and cisplatin for metastatic breast cancer. 1997 ·PubMed ·U. Klaassen, H. Wilke, Carolin Müller, (unknown), Michael Korn, W. Achterrath, A. Harstrick, (unknown), S. Seeber	2
16	Preclinical and clinical study results of the combination of paclitaxel and 5-fluorouracil/folinic acid in the treatment of metastatic breast cancer. 1996 ·PubMed ·U. Klaassen, A. Harstrick, H. Wilke, S. Seeber	13
17	Activity of N-benzyl-adriamycin-14-valerate (AD198), a new anthracycline derivate, in multidrug resistant human ovarian and breast carcinoma cell lines 1995 ·Anti-Cancer Drugs ·A. Harstrick, U. Vanhoefer, (unknown), (unknown), Joachim Baumgart, M. E. Scheulen, (unknown), S. Seeber	8
18	360 Phase I/II study with paclitaxel in combination with weekly high dose 5-FU/Folinic acid in the treatment of metastatic breast cancer 1995 ·European Journal of Cancer ·U. Klaassen, Hans‐Joachim Wilke, Dirk Strumberg, (unknown), A. Harstrick, Wilfried Eberhardt, Michael Korn, (unknown), R. Becher, S. Seeber	6
19	The neu-oncogene product in serum and tissue of patients with breast carcinoma 1993 ·Annals of Oncology ·R. Kath, (unknown), (unknown), (unknown), (unknown), (unknown), S. Seeber	30
20	Results of the first ESMO examination in medical oncology, London 1989 1991 ·Annals of Oncology ·P. Alberto, Bernadette Mermillod, (unknown), M. Schneider, S. Seeber, (unknown), J. M. A. Whitehouse, H. Cortés-Funes	4

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact